Bimervax, cjepivo protiv COVID-19 (rekombinantno, adjuvantirano)
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Bimervax, cjepivo protiv COVID-19 (rekombinantno, adjuvantirano) |
|---|---|
| Active Substance | fuzijski heterodimer domene za vezanje na receptor rekombinantnog proteina ĊĦiljka virusa SARS-CoV-2 |
| Prescription | na recept |
| Type of prescription | neponovljivi recept |
| Distribution | u ljekarni |
| ATC Code | J07BN |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
